Fluticasone | CAS# 90566-53-3 | Glucocorticoid Receptor Agonist

MedKoo Cat#: 130574 | Name: Fluticasone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluticasone is a glucocorticoid receptor agonist, resulting in the activation of lipocortin. This inhibits cytosolic phospholipase A2 and induces mitogen-activated protein kinase (MAPK) phosphatase 1, leading to dephosphorylation and inactivation of Jun N-terminal kinase, blocking NFkappaB transcriptional activity.

Chemical Structure

Fluticasone

CAS#90566-53-3

Theoretical Analysis

MedKoo Cat#: 130574

Name: Fluticasone

CAS#: 90566-53-3

Chemical Formula: C22H27F3O4S

Exact Mass: 444.1582

Molecular Weight: 444.51

Elemental Analysis: C, 59.45; H, 6.12; F, 12.82; O, 14.40; S, 7.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

948566-12-9 80474-14-2 (propionate) 397864-44-7 (furoate)

Synonym

Flovent, Flonase, Cutivate, Armonair, Xhance; Fluticasona; Fluticasonum; Fluticaps

IUPAC/Chemical Name

S-(Fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate

InChi Key

MGNNYOODZCAHBA-GQKYHHCASA-N

InChi Code

InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1

SMILES Code

O=C([C@@]1(O)[C@H](C)C[C@@]2([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)=O)SCF

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 444.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. Zhang M, Si SJ, Dai WJ, Yang J, Wang Y, Wei XR, Liu S, Xu CY, Zhang C, Jin F, Jiang LQ. A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment. Colloids Surf B Biointerfaces. 2023 May 24;228:113364. doi: 10.1016/j.colsurfb.2023.113364. Epub ahead of print. PMID: 37290201. 2. Soe KK, Krikeerati T, Pheerapanyawaranun C, Niyomnaitham S, Phinyo P, Thongngarm T. Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis. Front Pharmacol. 2023 May 23;14:1184552. doi: 10.3389/fphar.2023.1184552. PMID: 37288109; PMCID: PMC10242043. 3. Passali D, Passali GC, Damiani V, Ciprandi G. Azelastine/fluticasone and allergic rhinitis in clinical practice. Eur Arch Otorhinolaryngol. 2023 Jun 5. doi: 10.1007/s00405-023-08006-9. Epub ahead of print. PMID: 37277684. 5. Eachus E, DeLamielleure LE, Mitha S, Rasul TF, Faiz A. Scalp, Oral, and Nail Pemphigus Vulgaris: Clinical Characteristics and a Review of the Literature. Cureus. 2023 Apr 30;15(4):e38334. doi: 10.7759/cureus.38334. PMID: 37261177; PMCID: PMC10228709. 6. Oosterholt S, Pavord ID, Brusselle G, Yorgancıoğlu A, Pitrez PM, Abhijith PG, Teli C, Pasqua OD. Modelling Asthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomised clinical trials. Br J Clin Pharmacol. 2023 May 23. doi: 10.1111/bcp.15801. Epub ahead of print. PMID: 37221636. 7. Feldman WB, Avorn J, Kesselheim AS, Gagne JJ. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers. JAMA Intern Med. 2023 May 22:e231245. doi: 10.1001/jamainternmed.2023.1245. Epub ahead of print. PMID: 37213116; PMCID: PMC10203971. 8. Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023 May 20;13(1):8183. doi: 10.1038/s41598-023-35223-3. PMID: 37210420; PMCID: PMC10199945. 9. Syverson EP, Tobin M, Patton T, Franciosi JP, Gupta SK, Venkatesh RD. Variability in Swallowed Topical Corticosteroid Practice Patterns for Treatment of Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 May 18. doi: 10.1097/MPG.0000000000003834. Epub ahead of print. PMID: 37204839. 10. Takahashi K, Kawayama T, Takamori A, Tashiro H, Kinoshita T, Takagi K, Yamasaki K, Machida K, Kawaguchi A, Yatera K, Inoue H; TRACK (Triple therapy for Japanese with mild to moderate COPD in Kyushu) study investigator group. Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study. BMJ Open Respir Res. 2023 May;10(1):e001607. doi: 10.1136/bmjresp-2022-001607. PMID: 37197795. 11. Enayati P, Dehdar K, Javan M, Raoufy MR. The protective effect of inhaled corticosteroid on lung inflammation and breathing pattern complexity in a rat model of asthma. Respir Physiol Neurobiol. 2023 May 12;314:104072. doi: 10.1016/j.resp.2023.104072. Epub ahead of print. PMID: 37182593. 12. Umeda A, Shimada H, Yamane T, Mochizuki T, Inoue Y, Tsushima K, Miyagawa K, Mochida A, Takeda H, Okada Y, Masaki K, Matsusaka M, Fukunaga K. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. Front Physiol. 2023 Apr 21;14:1131949. doi: 10.3389/fphys.2023.1131949. PMID: 37179838; PMCID: PMC10170765. 13. Castro K, Arostegui D, Schwarz S, Gandhi S, Peshimam J, Rabinowitz S, Pittman M, Wallach T. Histologically Remarkable Eosinophilic Esophagitis Responsive to Dupilumab in a Gastrostomy Tube-Dependent Pediatric Patient on Amino Acid Formula. JPGN Rep. 2022 Sep 1;3(4):e250. doi: 10.1097/PG9.0000000000000250. PMID: 37168474; PMCID: PMC10158404. 14. Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History. Int J Chron Obstruct Pulmon Dis. 2023 Apr 19;18:625-641. doi: 10.2147/COPD.S386962. PMID: 37155497; PMCID: PMC10122846. 15. Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm. 2023 May 3:1-16. doi: 10.18553/jmcp.2023.22373. Epub ahead of print. PMID: 37133429. 16. Wang J, Zou D, Li Y, Liu P, Guo C. Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system. Front Pharmacol. 2023 Apr 13;14:1161728. doi: 10.3389/fphar.2023.1161728. PMID: 37124229; PMCID: PMC10133538. 17. Vasudev M, Torabi SJ, Michelle L, Meller LLT, Birkenbeuel JL, Roman KM, Nguyen TV, Kuan EC. The rising cost of rhinologic medications. Ann Allergy Asthma Immunol. 2023 Apr 23:S1081-1206(23)00266-1. doi: 10.1016/j.anai.2023.04.013. Epub ahead of print. PMID: 37098404. 18. Ogata H, Sha K, Kotetsu Y, Enokizu-Ogawa A, Katahira K, Ishimatsu A, Taguchi K, Moriwaki A, Yoshida M. Tezepelumab treatment for allergic bronchopulmonary aspergillosis. Respirol Case Rep. 2023 Apr 17;11(5):e01147. doi: 10.1002/rcr2.1147. PMID: 37082171; PMCID: PMC10111631. 19. Drescher SK, Jiao Y, Chen MJ, Kurumaddali A, Shao J, Amini E, Hochhaus G, Bulitta JB. Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics. Pharm Res. 2023 May;40(5):1177-1191. doi: 10.1007/s11095-023-03472-6. Epub 2023 Apr 20. PMID: 37081302. 20. Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis". Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1. PMID: 37004642; PMCID: PMC10129919.